World Kidney Day 2010: Diabetic Kidney Disease-Act Now or Pay Later

American Journal of Kidney Diseases

Volumn 55, Issue 2, 2010, Pages 205-208

  Atkins, Robert C ^a   Zimmet, Paul ^b  

^a MONASH MEDICAL CENTRE   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEALTH PROMOTION; HUMANS; WORLD HEALTH;

EID: 74549184137     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.12.001     Document Type: Editorial

References (29)

1. International Diabetes Federation and International Society of Nephrology. Diabetes and kidney disease: time to act. http://www.idf.org/webdata/docs/Guide_Diabetes_Kidney.pdf Accessed November 30, 2009
2. Zimmet P., Alberti K., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 6865 (2001) 782-787
3. King H., Aubert R., and Herman W. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21 9 (1998) 1414-1431
4. Yoon K.H., Lee J.H., Kim J.W., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 368 9548 (2006) 1681-1688
5. Sicree R., Shaw J., and Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D. (Ed). Diabetes Atlas. 3rd ed. (2006), International Diabetes Federation, Brussels, Belgium 15-109
6. nd ed. (2008), John Wiley & Sons Ltd, Chichester, United Kingdom 499-518
7. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States (2007), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 239-254
8. Appendix II. In: McDonald S., Excell L., and Livingston B. (Eds). ANZDATA Registry Report 2008 (2008), Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia 1-97
9. Yamagata K., Iseki K., Nitta K., et al. Chronic kidney disease perspectives in Japan and the importance of urinalysis screening. Clin Exp Nephrol 12 1 (2008) 1-8
10. Lysaght M. Maintenance dialysis population dynamics: current trends and long term implications. J Am Soc Nephrol 13 suppl 1 (2002) S37-S40
11. Adler A.L., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 1 (2003) 225-232
12. Retnakaran R., Cull C.A., Thorne K.I., Adler A.I., Holamn R.R., and UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 55 6 (2006) 1832-1839
13. Parving H.H., Lewis J.B., Ravid M., Remuzzi G., Hunsicker L.G., and DEMAND investigators. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69 11 (2006) 2057-2063
14. Ninomiya T., Perkovic V., de Galan B.E., et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20 8 (2009) 1813-1821
15. Dunstan D.W., Zimmet P.Z., Welborn T.A., et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25 5 (2002) 829-834
16. White S.L., Polkinghorne K.R., Cass A., Shaw J., Atkins R.C., and Chadban S.J. Limited knowledge of kidney disease in a survey of AusDiab study participants. Med J Aust 188 4 (2008) 204-208
17. Whaley-Connell A., Sowers J.R., McCullough P.A., et al. Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 53 4 (2009) S11-S21 (suppl 4)
18. Thomas M., Viberti G., and Groop P. Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat Clin Pract Nephrol 4 1 (2008) 2-3
19. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 15 (2008) 1577-1589
20. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?. Diabet Med 25 suppl 2 (2008) 25-29
21. Gaede P., Lund-Andersen H., Parving H.H., Pedersen O., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 6 (2008) 580-591
22. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 9590 (2007) 829-840
23. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 24 (2008) 2560-2572
24. Zoungas S., de Galan B.E., Ninomiya T., et al. The combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes; new results from ADVANCE. Diabetes Care 32 11 (2009) 2068-2074
25. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 19 (2004) 1941-1951
26. Parving H.H., Lehnert H., Bröchner-Mortensen J., et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 12 (2001) 870-878
27. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 345 12 (2001) 851-860
28. Burney B., Kalaitzidis R., and Bakris G. Novel therapies of diabetic nephropathy. Curr Opin Nephrol Hypertens 18 2 (2009) 107-111
29. Atkins R., Perico N., Codreanu I., Peng L., Remuzzi G., and ISN COMGAN Research Committee. Program for Detection and Management of Chronic Kidney Disease, Hypertension, Diabetes and Cardiovascular Disease in Developing Countries. http://www.nature.com/isn/education/guidelines/isn/pdf/ed_051027_2x1.pdf Accessed November 30, 2009